View ValuationKangstem Biotech 将来の成長Future 基準チェック /06現在、 Kangstem Biotechの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長23.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2024 fiscal period end). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).お知らせ • Mar 14Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 30, 2026Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 60, haan-ro, gyeonggi-do, gwangmyeong South KoreaNew Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2024 fiscal period end). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$98.9m).New Risk • Sep 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩123.2b market cap, or US$88.5m).お知らせ • Aug 20Kangstem Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 36.632 billion.Kangstem Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 36.632 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 38,000,000 Price\Range: KRW 964 Discount Per Security: KRW 12.532 Transaction Features: Rights OfferingNew Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩79.7b market cap, or US$57.9m).お知らせ • Jun 11Kangstem Biotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.21 billion.Kangstem Biotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.21 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 38,000,000 Price\Range: KRW 1295 Discount Per Security: KRW 16.835 Transaction Features: Rights OfferingNew Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₩113.5b market cap, or US$82.2m).お知らせ • Feb 27Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 26, 2025Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 60, haan-ro, gyeonggi-do, gwangmyeong South KoreaNew Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (48% increase in shares outstanding). Market cap is less than US$100m (₩106.6b market cap, or US$76.5m).分析記事 • Sep 24Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • May 24Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Apr 26An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. (KOSDAQ:A217730) for KRW 2.8 billionAn undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. (KOSDAQ:A217730) for KRW 2.8 billion on April 25, 2024.Reported Earnings • Mar 16Full year 2023 earnings released: ₩541 loss per share (vs ₩533 loss in FY 2022)Full year 2023 results: ₩541 loss per share (further deteriorated from ₩533 loss in FY 2022). Revenue: ₩12.7b (down 22% from FY 2022). Net loss: ₩21.9b (loss widened 8.5% from FY 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.分析記事 • Mar 06Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) TunnelWith a price-to-sales (or "P/S") ratio of 6.9x Kangstem Biotech Co., Ltd. ( KOSDAQ:217730 ) may be sending bullish...New Risk • Nov 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (47% increase in shares outstanding). Market cap is less than US$100m (₩75.2b market cap, or US$58.4m).New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 5.4% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩61.2b market cap, or US$47.2m).New Risk • Aug 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩80.0b market cap, or US$59.9m).Reported Earnings • Mar 19Full year 2022 earnings released: ₩533 loss per share (vs ₩767 loss in FY 2021)Full year 2022 results: ₩533 loss per share (improved from ₩767 loss in FY 2021). Revenue: ₩16.3b (up 31% from FY 2021). Net loss: ₩20.2b (loss narrowed 5.2% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Non-executive Director Jung-Ho Choi was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 18Second quarter 2022 earnings released: ₩125 loss per share (vs ₩162 loss in 2Q 2021)Second quarter 2022 results: ₩125 loss per share. Revenue: ₩3.94b (up 51% from 2Q 2021). Net loss: ₩4.76b (loss widened 15% from 2Q 2021).Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Non-executive Director Jung-Ho Choi was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Is New 90 Day High Low • Feb 24New 90-day low: ₩6,850The company is down 4.0% from its price of ₩7,150 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.分析記事 • Feb 17Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Dec 26Would Shareholders Who Purchased Kang Stem Biotech's (KOSDAQ:217730) Stock Three Years Be Happy With The Share price Today?Kang Stem Biotech Co., Ltd. ( KOSDAQ:217730 ) shareholders should be happy to see the share price up 14% in the last...Is New 90 Day High Low • Sep 22New 90-day low: ₩7,340The company is down 31% from its price of ₩10,600 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Kangstem Biotech は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A217730 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20263,423-10,140-15,469-14,827N/A12/31/20253,572-10,482-12,335-11,676N/A12/31/20247,746-6,762-19,581-18,987N/A9/30/202412,775-10,089-15,497-14,580N/A6/30/202413,278-10,925-16,670-15,780N/A3/31/202412,160-20,640-17,633-16,633N/A12/31/202312,704-21,949-17,348-16,498N/A9/30/20239,807-19,299-18,813-18,339N/A6/30/202311,835-19,883-18,468-17,923N/A3/31/202314,620-19,800-18,933-18,198N/A12/31/202216,301-20,236-19,712-18,864N/A9/30/202215,423-22,709-21,278-20,356N/A6/30/202215,948-21,950-21,597-19,298N/A3/31/202214,614-21,338-21,851-17,692N/A12/31/202112,405-21,348-21,644-16,994N/A9/30/202110,712-18,841-18,093-13,543N/A6/30/20218,577-17,479-16,282-12,202N/A3/31/20219,101-16,172-17,084-14,765N/A12/31/20209,138-18,471-17,048-13,994N/A9/30/20208,608-23,751-21,037-15,849N/A6/30/20208,026-24,886-32,454-18,773N/A3/31/20206,475-27,651-28,892-13,189N/A12/31/20196,005-24,635N/A-13,322N/A9/30/20195,997-18,973N/A-12,134N/A6/30/20198,572-17,123N/A-8,997N/A3/31/20198,874-15,332N/A-13,169N/A12/31/20189,165-13,648N/A-11,477N/A9/30/20188,411-13,773N/A-10,552N/A6/30/20187,276-15,699N/A-11,862N/A3/31/20189,156-15,141N/A-10,863N/A12/31/20179,133-15,423N/A-10,647N/A9/30/20177,587-12,323N/A-11,028N/A6/30/20175,122-10,089N/A-8,876N/A12/31/2016843-8,300N/A-7,797N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A217730の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A217730の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A217730の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A217730の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A217730の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A217730の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/25 16:37終値2026/06/25 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Kangstem Biotech Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
New Risk • Mar 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2024 fiscal period end). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (13% average weekly change).
お知らせ • Mar 14Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 30, 2026Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 30, 2026, at 09:01 Tokyo Standard Time. Location: conference room, 60, haan-ro, gyeonggi-do, gwangmyeong South Korea
New Risk • Nov 14New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended September 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported September 2024 fiscal period end). Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩143.8b market cap, or US$98.9m).
New Risk • Sep 04New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 68% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (68% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩123.2b market cap, or US$88.5m).
お知らせ • Aug 20Kangstem Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 36.632 billion.Kangstem Biotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 36.632 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 38,000,000 Price\Range: KRW 964 Discount Per Security: KRW 12.532 Transaction Features: Rights Offering
New Risk • Jul 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₩79.7b market cap, or US$57.9m).
お知らせ • Jun 11Kangstem Biotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.21 billion.Kangstem Biotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 49.21 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 38,000,000 Price\Range: KRW 1295 Discount Per Security: KRW 16.835 Transaction Features: Rights Offering
New Risk • Jun 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Market cap is less than US$100m (₩113.5b market cap, or US$82.2m).
お知らせ • Feb 27Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 26, 2025Kangstem Biotech Co., Ltd., Annual General Meeting, Mar 26, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 60, haan-ro, gyeonggi-do, gwangmyeong South Korea
New Risk • Nov 07New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (48% increase in shares outstanding). Market cap is less than US$100m (₩106.6b market cap, or US$76.5m).
分析記事 • Sep 24Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 • May 24Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Apr 26An undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. (KOSDAQ:A217730) for KRW 2.8 billionAn undisclosed buyer agreed to acquire a 24.27% stake in Croen Inc. from Kangstem Biotech Co., Ltd. (KOSDAQ:A217730) for KRW 2.8 billion on April 25, 2024.
Reported Earnings • Mar 16Full year 2023 earnings released: ₩541 loss per share (vs ₩533 loss in FY 2022)Full year 2023 results: ₩541 loss per share (further deteriorated from ₩533 loss in FY 2022). Revenue: ₩12.7b (down 22% from FY 2022). Net loss: ₩21.9b (loss widened 8.5% from FY 2022). Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
分析記事 • Mar 06Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) TunnelWith a price-to-sales (or "P/S") ratio of 6.9x Kangstem Biotech Co., Ltd. ( KOSDAQ:217730 ) may be sending bullish...
New Risk • Nov 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 47% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.3% average weekly change). Shareholders have been diluted in the past year (47% increase in shares outstanding). Market cap is less than US$100m (₩75.2b market cap, or US$58.4m).
New Risk • Nov 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 5.4% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩61.2b market cap, or US$47.2m).
New Risk • Aug 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.2% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (9.6% average weekly change). Market cap is less than US$100m (₩80.0b market cap, or US$59.9m).
Reported Earnings • Mar 19Full year 2022 earnings released: ₩533 loss per share (vs ₩767 loss in FY 2021)Full year 2022 results: ₩533 loss per share (improved from ₩767 loss in FY 2021). Revenue: ₩16.3b (up 31% from FY 2021). Net loss: ₩20.2b (loss narrowed 5.2% from FY 2021). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Non-executive Director Jung-Ho Choi was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 18Second quarter 2022 earnings released: ₩125 loss per share (vs ₩162 loss in 2Q 2021)Second quarter 2022 results: ₩125 loss per share. Revenue: ₩3.94b (up 51% from 2Q 2021). Net loss: ₩4.76b (loss widened 15% from 2Q 2021).
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 1 highly experienced director. No independent directors (3 non-independent directors). Non-executive Director Jung-Ho Choi was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Is New 90 Day High Low • Feb 24New 90-day low: ₩6,850The company is down 4.0% from its price of ₩7,150 on 26 November 2020. The South Korean market is up 17% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 7.0% over the same period.
分析記事 • Feb 17Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 • Dec 26Would Shareholders Who Purchased Kang Stem Biotech's (KOSDAQ:217730) Stock Three Years Be Happy With The Share price Today?Kang Stem Biotech Co., Ltd. ( KOSDAQ:217730 ) shareholders should be happy to see the share price up 14% in the last...
Is New 90 Day High Low • Sep 22New 90-day low: ₩7,340The company is down 31% from its price of ₩10,600 on 24 June 2020. The South Korean market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 8.0% over the same period.